[Personalized therapy of lung cancer - current standard and future challenges].

Abstract excerpt

So called "personalized therapy" has revolutionized the care of non-small cell lung cancer (NSCLC). The discovery of more and more driver mutations in NSCLC has led to a molecular defined sub classification of lung cancer patients. For four driver mutations (EGFRmut, ALKtransl, ROS1transl, BRAF-V600mut) firstline approved drugs are available and became the treatment of choice. Further drugs are in clinical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Carcinoma, Non-Small-Cell Lung
• Share to BRAF gene